Literature DB >> 8190282

Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.

E H Aylward1, J Brandt, A M Codori, R S Mangus, P E Barta, G J Harris.   

Abstract

Previous investigations using linear CT measures found no evidence of caudate atrophy in asymptomatic persons who have the DNA haplotype linked to the Huntington's disease (HD) gene. We measured volumes of the caudate, putamen, and globus pallidus on MRIs of 10 gene marker-positive and 18 gene marker-negative asymptomatic at-risk persons. The volumes of all basal ganglia structures were significantly reduced in the marker-positive group, even after controlling for age, total brain volume, and minor neurologic signs. Discriminant function analysis using basal ganglia volumes and age as predictor variables correctly identified genetic status in 86% of subjects. These results indicate that basal ganglia volume is reduced before individuals become symptomatic with HD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190282     DOI: 10.1212/wnl.44.5.823

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  51 in total

1.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

2.  Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Authors:  Paul G Unschuld; Richard A E Edden; Aaron Carass; Xinyang Liu; Megan Shanahan; Xin Wang; Kenichi Oishi; Jason Brandt; Susan S Bassett; Graham W Redgrave; Russell L Margolis; Peter C M van Zijl; Peter B Barker; Christopher A Ross
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

3.  Neural bases of dysphoria in early Huntington's disease.

Authors:  Sergio Paradiso; Beth M Turner; Jane S Paulsen; Ricardo Jorge; Laura L Boles Ponto; Robert G Robinson
Journal:  Psychiatry Res       Date:  2008-01-15       Impact factor: 3.222

Review 4.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

5.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

Review 6.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 7.  "Pre-symptomatic" Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Handb Clin Neurol       Date:  2008

8.  Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.

Authors:  Susie M D Henley; Edward J Wild; Nicola Z Hobbs; Rachael I Scahill; Gerard R Ridgway; David G Macmanus; Roger A Barker; Nick C Fox; Sarah J Tabrizi
Journal:  J Neurol       Date:  2009-03-05       Impact factor: 4.849

9.  Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.

Authors:  Kevin M Biglan; Christopher A Ross; Douglas R Langbehn; Elizabeth H Aylward; Julie C Stout; Sarah Queller; Noelle E Carlozzi; Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

10.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation.

Authors:  J R Campodonico; A M Codori; J Brandt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.